Real‐World Treatment Patterns and Long‐Term Clinical Outcomes in Thai Patients With Acquired Haemophilia A
Haemophilia · 2025
DOI: 10.1111/hae.70028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Nonthakorn Hantrakun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Introduction
Data regarding long‐term clinical outcomes in Asian patients with acquired haemophilia A (AHA) was limited.
Aim
This study aimed to evaluate the effectiveness of current treatments and their outcomes in a real‐world setting among Thai patients with AHA.
Methods
This was a retrospective cohort study conducted at a university‐based hospital. Patients’ characteristics, treatment patterns and disease outcomes were collected. Univariate and multivariate Gray's competing risk analyses were used to examine the factors related to the time to disease response.
Results
From 2009 to 2022, 69 AHA patients with a median age of 68 years (range 36–97) were enrolled. The majority of cases were characterised by the absence of an underlying aetiology (82.6%) and presented as major bleeding (71.0%). As first‐line treatment, 79.7% were treated with steroid monotherapy, and 13.0% received a combination of steroid and rituximab. Thirty‐one patients (44.9%) received at least one dose of haemostatic agents. After a median time to follow‐up of 24.9 months (interquartile range 1.6–78.5), 41 patients (59.4%) attained first disease remission. Factor VIII below 1 IU/dL and the combination of steroid and rituximab were associated with time to disease remission, with subdistribution hazard ratio of 0.3 (95% confidence interval [CI], 0.1–0.7) and 5.2 (95% CI, 2.0–13.4), respectively. The most common complication in this cohort was infection (40.6%).
Conclusion
The combination of steroid and rituximab demonstrated efficacy in the management of AHA. In addition, infectious complications were a significant concern when treating AHA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Nonthakorn Hantrakun
Zitieren
APA
Hantrakun, N., Niprapan, P., Tuntivate, P., Wongsarikan, N., Norasetthada, L., Tantiworawit, A., Rattarittamrong, E., Chai-Adisaksopha, C., Rattanathammethee, T., Hantrakool, S., Piriyakhuntorn, P., & Punnachet, T. (2025). Real‐World Treatment Patterns and Long‐Term Clinical Outcomes in Thai Patients With Acquired Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.70028
Vancouver
Hantrakun N, Niprapan P, Tuntivate P, Wongsarikan N, Norasetthada L, Tantiworawit A, et al. Real‐World Treatment Patterns and Long‐Term Clinical Outcomes in Thai Patients With Acquired Haemophilia A. Haemophilia. 2025. doi:10.1111/hae.70028
BibTeX
@article{Hantrakun2025,
author = {Hantrakun, Nonthakorn and Niprapan, Piangrawee and Tuntivate, Pakinee and Wongsarikan, Nuttanun and Norasetthada, Lalita and Tantiworawit, Adisak and Rattarittamrong, Ekarat and Chai-Adisaksopha, Chatree and Rattanathammethee, Thanawat and Hantrakool, Sasinee and Piriyakhuntorn, Pokpong and Punnachet, Teerachat},
title = {Real‐World Treatment Patterns and Long‐Term Clinical Outcomes in Thai Patients With Acquired Haemophilia A},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70028}
}
EUVIMED